Regulatory Electronic Submission Preparation, Filing and Approval for Drugs, Medical Devices and Combination Products based on eCTD and STED Standards
1. Service Description
We offer electronic regulatory submission preparation services in US
and EU for Drugs, Medical Devices and Combination Products based on
eCTD and STED Standards
2. Cost Savings - Return on Investments (ROI)
Amount of money saved by your company on using our service based on the company size is provided in the Table 1.0.
Projected savings is based on
- Process efficiency gains (people)
- Less personnel requirements (people)
- Infrastructure efficiency gains (systems)
- Infrastructure validation and maintenance (systems)
- Delivering quality products
- Avoid regulatory noncompliance cost
- Avoid regulatory fines cost
Compared to cost associated with company's inefficient internal manual methods, , systems, tools, software’s, and personnel etc. Detailed Return on Investment (ROI) information is available on request.
| Company Size | Small | Medium | Large |
| $Savings |
≥ 20% |
≥
60% |
≥
80% |
| Annual Sales | ≤ $100 million |
$100 million < Sales
≤ $500 million |
> $500 million |
| Number of Submissions | ≤ 2 per year |
2 < Sub ≤ 4 per year |
> 4 per year |
Table 1.0 - Amount of money saved by your company on using our service. Company size is based on annual sales as per FDA classification.
3. Solution Approach
Regulatory electronic submission preparation service offered by us will
- Minimize the Impact on Approval, Launch, and Time-to-Peak Sales
- Implement Practical Approaches for Global CTD Submissions, Including Sample Submissions
- Evaluate Regulatory Differences between US, EU, HC, and Japan
- Prepare Applications in Multiple Submission Formats
- Plan, Develop and Validate Software that Produces eCTD: Accounting for Title 21 CFR Part 11
- Leverage the Efficiencies of XML Including Real World Examples
- Comprehensive Technology Focus on eCTD Enablers for amendments and supplements
- Submission Lifecycle Management using eCTD
- Build eCTD into Core Document Management Processes
The FDA regulatory marketing applications for drugs, devices, and other submissions services offered are summarized in Table 1.0.
|
No |
Regulatory Submission |
Drug/Biologics |
Device |
Purpose |
|
1 |
Clinical Trial Exemptions (Investigational Applications) |
IND |
IDE |
Allowance to begin testing in humans |
|
2 |
Marketing Applications |
NDA, BLA, ANDA |
PMA, PDP, 510(k) |
Authorization to begin product marketing |
|
3 |
Annual Reports, Adverse Event Reports and Promotional Materials |
AR, AERS, Promotional Material |
AR, AERS, Promotional Material |
Post-marketing requirements |
Table 1.0 United States Regulatory Marketing Applications Services
The European Union drugs and devices marketing application, and other submissions services offered are summarized in Table 2.0.
|
No |
Regulatory Submission |
Drug/Biologics |
Device |
Purpose |
|
1 |
Clinical Trial Exemptions (Investigational Applications) |
CTA Approval
CA Approval |
Notify Member States CA |
Allowance to begin testing in humans |
|
2 |
Marketing Applications |
EMEA Approval
·
Initial
applications
·
Supplementary information following validation
· Variation
submissions
· Renewal
submissions |
Declaration of Conformity Approval by a Notified Body and CE Mark
with Notified Body Number |
Authorization to begin product marketing |
|
3 |
Annual Reports, Adverse Event Reports and Promotional Materials |
EMEA
· Periodic
Safety Update Reports (PSURs)
· Follow-up
measures (FUMs) |
Inform Member State and CA.
Member state to inform European Commission |
Post-marketing requirements |
Table 2.0 European Union Regulatory Marketing Applications
The FDA ESG supports following submissions in eCTD format. Source FDA Electronic Submissions Gateway User Guide
|
Center |
Submissions |
|
CBER |
AERS –
Adverse Event Reports
AERS
Attachments
BLA –
Biologics License Application (eCTD and eBLA format)
IDE –
Investigational Device Exemption
IND –
Investigational New Drug Application (eCTD and eIND format)
DMF –
Drug Master File
Promotional Materials
Lot
Distribution Data |
|
CDER |
AERS –
Adverse Event Reports
AERS
Attachments
ANDA –
Abbreviated New Drug Application
BLA –
Biologics License Application
NDA –
New Drug Application
IND –
Investigational New Drug Application |
|
CDRH |
Adverse Events - Medical Device Reporting (MDR)
Electronic Submissions
510(k)
Notification
PMA –
Pre-market Approval
Medical Device Reporting (MDR) |
|
CVM |
Electronic Submissions |
Table 3.0. List of Electronic Submissions Supported by the FDA ESG. Source FDA Electronic Submissions Gateway User Guide.
We provide the standard template directory structure for all the modules as listed in Table 4.0 conforming to CTD specifications.
|
Module Name |
Description |
Folder Name |
|
Module 1 |
Administrative Information and Prescribing Information (Regional
Information) |
m1 |
|
Module 2 |
Summaries of Quality, Non-clinical Overview, Clinical Overview,
Non-clinical Summary, and Clinical Summary |
m2 |
|
Module 3 |
Quality |
m3 |
|
Module 4 |
Non Clinical Study Reports |
m4 |
|
Module 5 |
Clinical Study Reports |
m5 |
Table 4.0 CTD Module Name, Description, and Corresponding Electronic Folder Name

Figure 1 - The New Drug Development Process - Steps from Test Tube to New Drug Application Review - Source FDA

Figure 2 - Phases of Product Development, Years, Test Population, Purpose and Success Rate

Figure 3 - US FDA and EU Innovative IVD Marketing Approval Steps Summary

Figure 4 - Workflow Steps for Electronic Submissions

Figure 5 - Common Technical Documentation (CTD) Triangle

Figure 6 - Source and application of the STED (Source - GHTF STED, 2008, 7)
4. Definitions
Common Technical Document (CTD): A harmonized format for a regulatory dossier that is considered acceptable in Japan, Europe, the United States and Canada.
eCTD: The electronic format of the ICH Common Technical Document
STED: Summary Technical Documentation for Demonstrating Conformity to the Essential Principles of Safety and Performance of Medical Devices.
What is the CE Mark?
The CE Mark is a product-conformity and labeling requirement for any regulated product (e.g. electrical equipment and medical devices) placed for sale in the European market. Placing the CE (Conformitè Europèenne) label on a product indicates that the product complies with the applicable European Directives (i.e. the European Union Law) relating to the health, safety, environment and consumer protection requirements of that product type.
The CE Mark Declaration of Conformity: The Declaration of Conformity is a document which defines the specific EU directive against which the CE Mark is being claimed. It can also detail the specific international standards to which the product has been tested and approved. The Declaration of Conformity is required to be available and to be reviewed by customs authorities and regulatory agents when shipped to an EU member state.
Product Licenses and Safety Certification: To support the claims described in the Declaration of Conformity, Company has to maintain product licenses and certifications granted by Notified Bodies.
Instrumentation, both the IVD and RUO products, are safety tested and certified for CE Marking by Notified bodies like TÜV America
5. Applicable Laws, Regulations and Standards
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2004). ICH M2 EWG – Electronic Common Technical Document Specification. http://estri.ich.org/eCTD/eCTD_Specification_v3_2.pdf
- Food and Drug Administration, CDRH. (2008). Guidance on Electronic Regulatory Submissions and Review (ERSR). http://www.fda.gov/cder/regulatory/ersr/default.htm
- Global Harmonization Task Force (GHTF). (2008). Principles of Conformity Assessment for Medical Devices. http://www.ghtf.org/documents/sg1/SG1N40%202006-Conformity-Assessment-FINAL.pdf
- Global Harmonization Task Force (GHTF). (2008). Summary Technical Documentation for Demonstrating Conformity to the Essential Principles of Safety and Performance of Medical Devices (STED). http://www.ghtf.org/documents/sg1/SG1-PD-N011-sted.pdf

